Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy

被引:92
|
作者
Devillier, Raynier [1 ]
Coso, Diane [1 ]
Castagna, Luca [1 ,2 ]
Rossi, Isabelle Brenot [3 ]
Anastasia, Antonella [2 ]
Chiti, Arturo [4 ]
Ivanov, Vadim [1 ]
Schiano, Jean Marc [1 ]
Santoro, Armando [2 ]
Chabannon, Christian [1 ,5 ,6 ]
Balzarotti, Monica [2 ]
Blaise, Didier [1 ,5 ,6 ]
Bouabdallah, Reda [1 ]
机构
[1] Inst J Paoli I Calmettes, Dept Hematol, Transplantat & Cell Therapy Program, F-13009 Marseille, France
[2] Ist Clin Humanitas, Humanitas Canc Ctr, Hematol Unit, Milan, Italy
[3] Inst J Paoli I Calmettes, Dept Nucl Med, F-13009 Marseille, France
[4] Ist Clin Humanitas, Humanitas Canc Ctr, Nucl Med Unit, Milan, Italy
[5] Inst J Paoli I Calmettes, INSERM, CBT 510, Ctr Invest Clin Biotherapie, F-13009 Marseille, France
[6] Univ Aix Marseille, Fac Med, Inst J Paoli I Calmettes, Marseille, France
来源
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2012年 / 97卷 / 07期
关键词
Hodgkin's lymphoma; PET; outcome; relapsed refractory; ASCT; HIGH-DOSE CHEMOTHERAPY; PROGNOSTIC-FACTORS; FDG-PET; DISEASE; MULTICENTER; FAILURE; SCORE;
D O I
10.3324/haematol.2011.056051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background High-dose chemotherapy followed by autologous stem cell transplantation is the standard treatment for relapsed and/or refractory Hodgkin's lymphoma although half of patients relapse after transplantation. Predictive factors, such as relapse within 12 months, Ann-Arbor stage at relapse, and relapse in previously irradiated fields are classically used to identify patients with poor outcome. Recently, 18-fluorodeoxyglucose positron emission tomography has emerged as a new method for providing information to predict outcome. The aim of this study was to confirm the predictive value of positron emission tomography status after salvage therapy and to compare single versus tandem autologous stem cell transplantation in patients with relapsed and/or refractory Hodgkin's lymphoma. Design and Methods We report a series of 111 consecutive patients with treatment-sensitive relapsed and/or treatment-refractory Hodgkin's lymphoma who achieved complete (positron emission tomography-negative group) or partial remission (positron emission tomography-positive group) at positron emission tomography evaluation after salvage chemotherapy and who underwent single or tandem autologous stem cell transplantation. Results Five-year overall and progression-free survival rates were 81% and 64%, respectively. There were significant differences in 5-year progression-free survival (79% versus 23%; P<0.001) and 5-year overall survival (90% versus 55%, P=0.001) between the positron emission tomography-negative and -positive groups, respectively. A complete response, as determined by positron emission tomography evaluation, after salvage therapy predicted significantly better 5-year overall survival rates in both intermediate (91% versus 50%; P=0.029) and unfavorable (89% versus 58%; P=0.026) risk subgroup analyses. In the positron emission tomography-positive subgroup, tandem transplantation improved 5-year progression-free survival from 0% (in the single transplantation group) to 43% (P=0.034). Multivariate analysis showed that positron emission tomography status (hazard ratio: 5.26 [2.57-10.73]) and tandem transplantation (hazard ratio: 0.39 [0.19-0.78]) but not risk factors at relapse (hazard ratio: 1.77 [0.80-3.92]) significantly influenced progression-free survival, while only tomography status significantly influenced overall survival (hazard ratio: 4.03 [1.38-11.75]). Conclusions In patients with relapsed/refractory Hodgkin's lymphoma responding to prior salvage therapy, positron emission tomography response at time of autologous stem cell transplantation favorably influences outcome and enables identification of patients requiring single or tandem transplantation.
引用
收藏
页码:1073 / 1079
页数:7
相关论文
共 50 条
  • [21] Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant
    Cherng, Hua-Jay J.
    Xu, Guofan
    Feng, Lei
    Steiner, Raphael
    Fayad, Luis
    Strati, Paolo
    Nair, Ranjit
    Nastoupil, Loretta J.
    Lee, Hun Ju
    Neelapu, Sattva S.
    Flowers, Christopher R.
    Rodriguez, Maria
    Wang, Michael
    Hagemeister, Fredrick
    Pinnix, Chelsea C.
    Ramdial, Jeremy
    Srour, Samer
    Nieto, Yago
    Rezvani, Katayoun
    Champlin, Richard
    Kebriaei, Partow
    Westin, Jason
    Macapinlac, Homer A.
    Shpall, Elizabeth
    Ahmed, Sairah
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (01) : 35 - 44
  • [22] Combination of Brentuximab Vedotin and Pembrolizumab as Salvage Treatment Before Autologous Stem Cell Transplantation and Maintenance in Patients with Relapsed/Refractory Hodgkin Lymphoma
    Massa, Hanne
    Massaro, Fulvio
    Maerevoet, Marie
    BIOMEDICINES, 2025, 13 (02)
  • [23] High-dose chemotherapy and peripheral hematopoietic stem cell transplantation in relapsed/refractory Hodgkin's lymphoma
    Kelta, Mouhammed
    Zekri, Jamal
    Abdelghany, Ehab
    Rehman, Jalil Ur
    Khan, Zahid Amin
    Al-Saadil, Rawan
    Dadai, Reyad
    TUMORI JOURNAL, 2018, 104 (06): : 471 - 475
  • [24] Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation
    Kaloyannidis, Panayotis
    Hertzberg, Mark
    Webb, Kate
    Zomas, Athanasios
    Schrover, Rudolf
    Hurst, Michael
    Jacob, Ian
    Nikoglou, Thalia
    Connors, Joseph M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (04) : 540 - 549
  • [25] F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma
    Gentzler, Ryan D.
    Evens, Andrew M.
    Rademaker, Alfred W.
    Weitner, Bing B.
    Mittal, Bharat B.
    Dillehay, Gary L.
    Petrich, Adam M.
    Altman, Jessica K.
    Frankfurt, Olga
    Variakojis, Daina
    Singhal, Seema
    Mehta, Jayesh
    Williams, Stephanie
    Kaminer, Lynne
    Gordon, Leo I.
    Winter, Jane N.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (06) : 793 - 800
  • [26] Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning
    Isidori, Alessandro
    Christofides, Anna
    Visani, Giuseppe
    LEUKEMIA & LYMPHOMA, 2016, 57 (11) : 2499 - 2509
  • [27] Outcomes of Refractory and Relapsed Hodgkin Lymphoma With Autologous Stem-Cell Transplantation: A Single Institution Experience
    Wali, Rabia
    Saeed, Haleema
    Patrus, Naveed
    Javed, Shehla
    Khan, Saadiya Javed
    JOURNAL OF GLOBAL ONCOLOGY, 2019, 5 : 1 - 6
  • [28] Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma
    Bains, Tarunpreet
    Chen, Andy I.
    Lemieux, Andrew
    Hayes-Lattin, Brandon M.
    Leis, Jose F.
    Dibb, William
    Maziarz, Richard T.
    LEUKEMIA & LYMPHOMA, 2014, 55 (03) : 583 - 587
  • [29] Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma
    Broeckelmann, P. J.
    Mueller, H.
    Casasnovas, O.
    Hutchings, M.
    von Tresckow, B.
    Jurgens, M.
    McCall, S. J.
    Morschhauser, F.
    Fuchs, M.
    Borchmann, P.
    Moskowitz, C. H.
    Engert, A.
    ANNALS OF ONCOLOGY, 2017, 28 (06) : 1352 - 1358
  • [30] Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Single-Center Experience
    Matar, Charbel
    Ibrahim, Ali
    Alameddine, Raafat
    El Cheikh, Jean
    Bazarbachi, Ali
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S310 - S311